This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Illumina's (ILMN) Innovations Drive Growth, Cost Woes Linger
by Zacks Equity Research
Illumina (ILMN) is working on its goals to strengthen its foothold in the multi-billion gene sequencing market with some highly competitive products in its existing portfolio and pipeline.
Here's Why Investors Should Retain Haemonetics (HAE) For Now
by Zacks Equity Research
Investors are optimistic about Haemonetics's (HAE) better-than-expected results and robust segmental performance.
Alcon (ALC) Signs EYSUVIS-Buyout Deal With Kala Pharmaceuticals
by Zacks Equity Research
The acquisition of EYSUVIS complements Alcon's (ALC) Systane family of eye drops offering, strengthening its treatment options for dry eye disease.
Here's Why You Should Hold on to Exact Sciences (EXAS) Stock
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on impressive Q1 results and a bullish 2022 outlook.
Align Technology (ALGN) to Offer Asana Smiles With New Pact
by Zacks Equity Research
Align Technology's (ALGN) new partnership will give doctors access to an alternative that helps reduce manual processes and creates a clear view of Invisalign treatment workflows.
Align Technology (ALGN) Debuts Invisalign Outcome Simulator Pro
by Zacks Equity Research
The next-generation of Align Technology's (ALGN) advanced patient communication tool will help patients see their potential new smile after Invisalign treatment.
LabCorp (LH) Introduces Latest Assay for Skin Cancer Patients
by Zacks Equity Research
LabCorp's (LH) new assay is claimed to have shown a demonstrable clinical advantage in patients suffering from melanoma.
Globus Medical (GMED) Completes First Cases With Excelsius3D
by Zacks Equity Research
Globus Medical's (GMED) Excelsius3D, when combined with ExcelsiusGPS, facilitates greater implant placement accuracy, lowers radiation exposure and reduces operative times.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN (QGEN), owing to strong international growth and bullish guidance.
Here's Why Investors Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) better-than-expected results and robust segmental growth.
QIAGEN (QGEN) Unveils New Enhancements to QIAstat-Dx Portfolio
by Zacks Equity Research
The launch of QIAstat-Dx Rise and other advancements to the QIAstat-Dx portfolio are expected to strengthen QIAGEN's (QGEN) syndromic testing solutions.
Looking for a Growth Stock? 3 Reasons Why Medpace (MEDP) is a Solid Choice
by Zacks Equity Research
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Illumina's (ILMN) GRAIL, Intermountain Healthcare Expand Tie-Up
by Zacks Equity Research
Illumina (ILMN) subsidiary GRAIL's MCED blood test will be offered along with existing single cancer screenings to advance cancer care delivery through early detection.
Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet's (ZBH) better-than-expected revenues and robust performance across several geographies.
Here's Why You Should Hold STERIS (STE) Stock in Your Portfolio
by Zacks Equity Research
Investors are optimistic about STERIS (STE) due to its strong fiscal fourth-quarter results.
LabCorp (LH) Debuts At-home Collection Kit for Diabetes Testing
by Zacks Equity Research
LabCorp's (LH) at-home collection kit makes it effortless for consumers to understand their diabetes risk and health status using an innovative and approved collection device.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Strong performance across the Diabetes Care and EPD businesses is driving the top line for Abbott (ABT).
QIAGEN (QGEN) to Acquire Poland-Based Enzymes Manufacturer
by Zacks Equity Research
The latest acquisition of BLIRT will allow QIAGEN (QGEN) to tap into the high opportunities within the life science industry.
Medtronic's (MDT) Onyx Frontier DES Receives FDA Approval
by Zacks Equity Research
Medtronic's (MDT) Onyx Frontier DES is utilized to treat patients with CAD.
Here's Why You Should Retain Charles River (CRL) Stock for Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.
Here's Why Investors Should Retain Medtronic (MDT) Stock
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) rising market share gains and ongoing business recovery.
Here's Why You Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) better-than-expected earnings and robust segmental performance.
NEOGEN (NEOG) Introduces InfiniSEEK for Cattle Breeders
by Zacks Equity Research
NEOGEN's (NEOG) recent launch enables simultaneous low-pass whole genome sequencing and high-coverage genotyping at regions of interest.
Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Grow
by Zacks Equity Research
Alcon (ALC) delivers better-than-expected results in the first quarter, with strong performance across both franchises driving the top line.
STERIS (STE) Q4 Earnings Surpass Estimates, Gross Margin Rises
by Zacks Equity Research
Robust performances across all four reporting segments drive STERIS' (STE) fiscal fourth-quarter revenues.